Bosutinib Monohydrate
FDA-approved product (tablet, oral), marketed as Bosulif, Bosutinib Monohydrate.
- Registered studies
- 2
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Chronic myelogenous leukemia
- Myeloid leukemia
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Bcr-abl tyrosine kinase inhibitors
- FDA pharmacologic class
- Kinase Inhibitor FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA43.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli54.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae30.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis43.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
2registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Bosutinib Monohydrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- SaquinavirExisting use: HIV infection, HIV-1 infection, Viral disease49.4% AI-predicted activityagainst E. coli50+ registered studies
- Ibrexafungerp CitrateExisting use: Vulvovaginal candidiasis49.4% AI-predicted activityagainst E. coliNo documented evidence found
- Mobocertinib SuccinateExisting use: Neoplasm, Non-small cell lung carcinoma49.2% AI-predicted activityagainst E. coliNo documented evidence found
- SparsentanExisting use: IGA glomerulonephritis49.2% AI-predicted activityagainst E. coli11 registered studies
- Epinastine HydrochlorideExisting use: Allergic conjunctivitis, Allergic disease, Eye allergy49.0% AI-predicted activityagainst E. coli10 registered studies
- Omidenepag IsopropylExisting use: Ocular hypertension, Open-angle glaucoma49.0% AI-predicted activityagainst E. coli1 registered study
- LesinuradExisting use: Gout, Hyperuricemia49.0% AI-predicted activityagainst E. coli22 registered studies
- Imatinib MesylateExisting use: Acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and 7 more48.9% AI-predicted activityagainst E. coli50+ registered studies
- Prucalopride SuccinateExisting use: Constipation, Constipation disorder48.9% AI-predicted activityagainst E. coli7 registered studies
- FamciclovirExisting use: Eye infection, Genital herpes, Herpes Labialis and 3 more48.8% AI-predicted activityagainst E. coli25 registered studies
- AbemaciclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more48.7% AI-predicted activityagainst E. coli50+ registered studies
- Nintedanib EsylateExisting use: Idiopathic pulmonary fibrosis, Interstitial pneumonitis, Non-small cell lung carcinoma and 1 more48.5% AI-predicted activityagainst E. coli50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation
NCT04655391 · start 2022-06-25
Registered record
- Registry ID
- NCT04655391
- Conditions
- Recurrent Acute Myeloid Leukemia
- Interventions
- Bosutinib Monohydrate; Decitabine; Enasidenib Mesylate; Gilteritinib Fumarate; Glasdegib Maleate; Ivosidenib; Venetoclax
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Withdrawn
- Start
- 2022-06-25
- Completion
- 2023-12-15
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRecurrent Acute Myeloid LeukemiaInterventionBosutinib Monohydrate; Decitabine; Enasidenib Mesylate; Gilteritinib Fumarate +3 morePhasePhase 1Registry statusWithdrawnTesting the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
NCT03654768 · start 2018-10-24
Registered record
- Registry ID
- NCT03654768
- Conditions
- Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Interventions
- Bosutinib; Dasatinib; Laboratory Biomarker Analysis; Nilotinib; Ruxolitinib; Imatinib
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Active not recruiting
- Start
- 2018-10-24
- Completion
- 2028-07-01
- Enrolment
- 81
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveInterventionBosutinib; Dasatinib; Laboratory Biomarker Analysis; Nilotinib +2 morePhasePhase 2Registry statusActive not recruiting